Form D · Biotechnology

SynLife, Inc.

Cambridge, MA · CIK 0001748220

Offering snapshot reported Jul 27, 2018 · SEC filing

Reported sold
$700K
Offering amount: $700K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 10, 2018
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$350K$700KJul 27, 2018: $500,000.00Jul 27, 2018Jul 27, 2018: $700,000.00Jul 27, 2018

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$500,000 → $700,000

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 27, 2018Initial$500,000No comparison1SEC filing
Jul 27, 2018Amendment$700,000$200,000vs Jul 27, 20181SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-317958
The existing financing was extended by an additional $200,000 from the same investor.

Source: Form D, filed Jul 27, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tamar Erdfarb Executive
Jeremy Wertheimer Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1 Kendall Square, Suite B4401
Cambridge, MA, 02139